Growth Hormone Secretion in Thalassemic Patients
During the past 10 years significant achievements have been made in the treatment of p–thalassemia major. Nevertheless, the improved survival of these patients has led to the appearance of several complications, which now represent the major clinical problems in the disease. Endocrine disorders are very common, and growth failure is one of the most frequent. Short stature is present in approximately 30% of our thalassemic patients (n = 200). However, the pathogenesis of the growth disturbances of thalassemic patients has not yet been elucidated. The role of growth hormone (GH) deficiency in the growth impairment of these patients is controversial. Hence, we have studied GH secretion in a group of thalassemic patients with short stature.
KeywordsShort Stature Standard Deviation Score Thalassemic Patient Thalassemia Major Transfusion Regimen
Unable to display preview. Download preview PDF.
- 1.Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein H (1975) Assessment of skeletal maturity and prediction of adult height (TW2 method). Academic, LondonGoogle Scholar
- 6.Rivolta MR, De Micheli A, Capra M, Gelosa M, Lange E, Monguzzi W (1987) Growth hormone response to hypoglycemic stress in thalassemia major (Abstr). J Endocrinol Invest 10 [Suppl] 4: 84Google Scholar